Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

“The development of Muse, a result of our ongoing collaboration with OpenAI and Formation Bio, represents another proof point ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Sanofi and Sudair Pharma Company (SPC) have joined forces to establish a state-of-the-art manufacturing facility within the Kingdom of Saudi Arabia, dedicated to the full production including delivery ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after ...

In collaboration with AstraZeneca Plc AZN, which is responsible for manufacturing ... The company reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. Sanofi expects ...

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...